

Corrigendum

# Corrigendum to: Development of bispecific antibodies in China: overview and prospects

Jing Zhang, Jizu Yi \* and Pengfei Zhou\*

Wuhan YZY Biopharma Co., Ltd, Biolake City C2-1, No. 666 Gaoxin Road, Wuhan, Hubei 430075, China

*Antibody Therapeutics*, 2021, doi: <https://doi.org/10.1093/abt/tbaa011>

In the originally published version of this manuscript, the following conflict of interest statement was omitted: “The authors are employees of Wuhan YZY Biopharma Co., Ltd that develops and commercializes antibody therapeutics including bispecific antibodies.” This has been corrected.

---

\*To whom correspondence should be addressed. Jizu Yi or Pengfei Zhou. Email: [yijizu@zybio.com](mailto:yijizu@zybio.com) or [pfzhou@zybio.com](mailto:pfzhou@zybio.com).